Fluoxetine

• 

  Subject Areas on Research

  • A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients. 
  • A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. 
  • A multicenter, double-blind comparison of the effects of nefazodone and fluoxetine on sleep architecture and quality of sleep in depressed outpatients. 
  • A new model of the blood--brain barrier: co-culture of neuronal, endothelial and glial cells under dynamic conditions. 
  • A psychometric evaluation of the CDRS and MADRS in assessing depressive symptoms in children. 
  • Achievement and maintenance of sustained response during the Treatment for Adolescents With Depression Study continuation and maintenance therapy. 
  • Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms. 
  • Acute time to response in the Treatment for Adolescents with Depression Study (TADS). 
  • Amygdala reactivity is inversely related to level of cannabis use in individuals with comorbid cannabis dependence and major depression. 
  • An abbreviated version of the Connor-Davidson Resilience Scale (CD-RISC), the CD-RISC2: psychometric properties and applications in psychopharmacological trials. 
  • An exploratory analysis of the impact of family functioning on treatment for depression in adolescents. 
  • Analysis of responses to serotonin in the pulmonary vascular bed of the cat. 
  • Antidepressant actions of histone deacetylase inhibitors. 
  • Antidepressant-like effects of cranial stimulation within a low-energy magnetic field in rats. 
  • Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder? 
  • Assessment of safety and long-term outcomes of initial treatment with placebo in TADS. 
  • Bespoke library docking for 5-HT2A receptor agonists with antidepressant activity. 
  • Brain fluoxetine measurements using fluorine magnetic resonance spectroscopy in patients with social phobia. 
  • Clinical and treatment response characteristics of late-life depression associated with vascular disease: a pooled analysis of two multicenter trials with sertraline. 
  • Clinician, parent, and child prediction of medication or placebo in double-blind depression study. 
  • Cognitive measures of adolescent depression: unique or unitary constructs? 
  • Combination pharmacotherapy: a mixture of small doses of naltrexone, fluoxetine, and a thyrotropin-releasing hormone analogue reduces alcohol intake in three strains of alcohol-preferring rats. 
  • Combining antidepressant medications: a good idea? 
  • Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder. 
  • Comparative efficacy of cognitive behavioral therapy, fluoxetine, and their combination in depressed adolescents: initial lessons from the treatment for adolescents with depression study. 
  • Cortical-amygdalar circuit dysfunction in a genetic mouse model of serotonin deficiency. 
  • Cost-effectiveness of treatments for adolescent depression: results from TADS. 
  • Cyclophosphamide-induced cystitis results in NLRP3-mediated inflammation in the hippocampus and symptoms of depression in rats. 
  • Daily process methodology for measuring earlier antidepressant response. 
  • Davidson Trauma Scale (DTS): normative scores in the general population and effect sizes in placebo-controlled SSRI trials. 
  • DeltaFosB in brain reward circuits mediates resilience to stress and antidepressant responses. 
  • Derivation of the SPAN, a brief diagnostic screening test for post-traumatic stress disorder. 
  • Differential ontogeny of opioid, dopaminergic and serotonergic regulation of prolactin secretion. 
  • Does antidepressant therapy improve cognition in elderly depressed patients? 
  • Drug-induced reductions in ethanol intake in alcohol preferring and Fawn-Hooded rats. 
  • Dystonia as a side effect of nonneuroleptics. 
  • Effects of fluoxetine at antidepressant doses on short-term outcome of detoxified alcoholics. 
  • Effects of fluoxetine on the polysomnogram in outpatients with major depression. 
  • Electrical alternans and hemodynamics in the anesthetized guinea pig can discriminate the cardiac safety of antidepressants. 
  • Empirically derived subtypes of adolescent depression: latent profile analysis of co-occurring symptoms in the Treatment for Adolescents with Depression Study (TADS). 
  • Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. 
  • Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression. 
  • Exposure to SSRI-type antidepressants increases righting time in the marine snail Ilyanassa obsoleta. 
  • Extreme thinking in clinically depressed adolescents: Results from the Treatment for Adolescents with Depression Study (TADS). 
  • Factor structure and psychometric properties of the Children's Negative Cognitive Error Questionnaire with a clinically depressed adolescent sample. 
  • Fear, avoidance and physiological symptoms during cognitive-behavioral therapy for social anxiety disorder. 
  • Fluorine magnetic resonance spectroscopy measurement of brain fluvoxamine and fluoxetine in pediatric patients treated for pervasive developmental disorders. 
  • Fluoxetine Maintains a State of Heightened Responsiveness to Motor Training Early After Stroke in a Mouse Model. 
  • Fluoxetine and oculomotor activity during sleep in depressed patients. 
  • Fluoxetine in child and adolescent depression: acute and maintenance treatment. 
  • Fluoxetine in post-traumatic stress disorder. Randomised, double-blind study. 
  • Fluoxetine increases suicide ideation less than placebo during treatment of adults with minor depressive disorder. 
  • Fluoxetine reduces saccharin-induced elevation of fluid intake in alcohol-preferring Fawn-Hooded rats. 
  • Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. 
  • Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents. 
  • Fluoxetine versus trazodone in the treatment of outpatients with major depression. 
  • Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. 
  • Functioning and quality of life in the Treatment for Adolescents with Depression Study (TADS). 
  • Gender difference in cocaine-induced HPA axis activation. 
  • Generalized social anxiety disorder and avoidant personality disorder: structural analysis and treatment outcome. 
  • Genetic serotonin deficiency and alcohol preference in the fawn hooded rats. 
  • Goldenhar syndrome associated with prenatal maternal Fluoxetine ingestion: Cause or coincidence? 
  • Hyperhidrosis in social anxiety disorder. 
  • Impact of childhood trauma on treatment outcome in the Treatment for Adolescents with Depression Study (TADS). 
  • Impact of depressive symptoms on the treatment of generalized social anxiety disorder. 
  • Lack of efficacy for fluoxetine in PTSD: a placebo controlled trial in combat veterans. 
  • Lower anxiogenic effects of serotonin agonists are associated with lower activation of amygdala and lateral orbital cortex in adolescent male rats. 
  • Maintenance therapy with fluoxetine in posttraumatic stress disorder: a placebo-controlled discontinuation study. 
  • Mental health service use among adolescents following participation in a randomized clinical trial for depression. 
  • Models of dopaminergic and serotonergic signaling. 
  • Multiple imputation for harmonizing longitudinal non-commensurate measures in individual participant data meta-analysis. 
  • Neural adaptation in imipramine-treated rats processed in forced swim test: assessment of time course, handling, rat strain and amine uptake. 
  • Noradrenergic control of cortico-striato-thalamic and mesolimbic cross-structural synchrony. 
  • Olanzapine and fluoxetine administration and coadministration increase rat hippocampal pregnenolone, allopregnanolone and peripheral deoxycorticosterone: implications for therapeutic actions. 
  • Onset of alcohol or substance use disorders following treatment for adolescent depression. 
  • Parental marital discord and treatment response in depressed adolescents. 
  • Perceived stress in anxiety disorders and the general population: a study of the Sheehan stress vulnerability scale. 
  • Pharmacotherapy of posttraumatic stress disorder: treatment options, long-term follow-up, and predictors of outcome. 
  • Potential fluoxetine chloride (Prozac) toxicity in a newborn. 
  • Prediction of response to fluoxetine and placebo in children and adolescents with major depression: a hypothesis generating study. 
  • Predictors and moderators of acute outcome in the Treatment for Adolescents with Depression Study (TADS). 
  • Predictors of hopelessness among clinically depressed youth. 
  • Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. 
  • Quality of life and posttraumatic stress disorder: a pilot study assessing changes in SF-36 scores before and after treatment in a placebo-controlled trial of fluoxetine. 
  • Radiologic correlates of antidepressant-induced delirium: the possible significance of basal-ganglia lesions. 
  • Randomized, placebo-controlled trial of fluoxetine for acute treatment of minor depressive disorder. 
  • Recovery and recurrence following treatment for adolescent major depression. 
  • Relative cost-effectiveness of treatments for adolescent depression: 36-week results from the TADS randomized trial. 
  • Remission and recovery in the Treatment for Adolescents with Depression Study (TADS): acute and long-term outcomes. 
  • Remission and residual symptoms after short-term treatment in the Treatment of Adolescents with Depression Study (TADS). 
  • Research knowledge among the participants in the Treatment for Adolescents With Depression Study (TADS). 
  • Resolution of fear of flying with fluoxetine treatment. 
  • Response characteristics to antidepressants and placebo in post-traumatic stress disorder. 
  • Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. 
  • SPRINT: a brief global assessment of post-traumatic stress disorder. 
  • SSRI Augmentation by 5-Hydroxytryptophan Slow Release: Mouse Pharmacodynamic Proof of Concept. 
  • Second-Generation Antipsychotics in Management of Acute Pediatric Bipolar Depression: A Systematic Review and Meta-analysis. 
  • Selective serotonin reuptake inhibitors for fibromyalgia syndrome. 
  • Serotonin syndrome produced by a combination of fluoxetine and lithium. 
  • Serotonin synthesis, release and reuptake in terminals: a mathematical model. 
  • Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. 
  • Social problem-solving among adolescents treated for depression. 
  • Sociotropy and autonomy: relationship to antidepressant drug treatment response and endogenous-nonendogenous dichotomy. 
  • Structure-based discovery of conformationally selective inhibitors of the serotonin transporter. 
  • Study refusal and exclusion from a randomized treatment study of generalized social phobia. 
  • Suicidal events in the Treatment for Adolescents With Depression Study (TADS). 
  • Symptom-specific effects of fluoxetine in post-traumatic stress disorder. 
  • The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes. 
  • The Treatment for Adolescents With Depression Study (TADS): outcomes over 1 year of naturalistic follow-up. 
  • The Treatment for Adolescents with Depression Study (TADS): methods and message at 12 weeks. 
  • The alpha(2a)-adrenergic receptor plays a protective role in mouse behavioral models of depression and anxiety. 
  • The effects of extended evaluation on depressive symptoms in children and adolescents. 
  • The effects of fluoxetine on the polysomnogram of depressed outpatients: a pilot study. 
  • The eight-item treatment-outcome post-traumatic stress disorder scale: a brief measure to assess treatment outcome in post-traumatic stress disorder. 
  • The feasibility of a randomised, placebo-controlled clinical trial of homeopathic treatment of depression in general practice. 
  • The modifying effect of the serum-to-dialysate potassium gradient on the cardiovascular safety of SSRIs in the hemodialysis population: a pharmacoepidemiologic study. 
  • The role of readiness to change in response to treatment of adolescent depression. 
  • Tolerability of fluoxetine in posttraumatic stress disorder. 
  • Trajectories of Functioning Into Emerging Adulthood Following Treatment for Adolescent Depression. 
  • Trauma, resilience and saliostasis: effects of treatment in post-traumatic stress disorder. 
  • Treating depression and oppositional behavior in adolescents. 
  • Treatment for Adolescents With Depression Study (TADS): rationale, design, and methods. 
  • Treatment for Adolescents with Depression Study (TADS): safety results. 
  • Treatment of insomnia in depressed insomniacs: effects on health-related quality of life, objective and self-reported sleep, and depression. 
  • Treatment response in depressed adolescents with and without co-morbid attention-deficit/hyperactivity disorder in the Treatment for Adolescents with Depression Study. 
  • Tridimensional Personality Questionnaire and serotonin in bulimia nervosa. 
• 

  Keywords of People

  • Bradford, Daniel William, Professor of Psychiatry and Behavioral Sciences, Psychiatry, Child & Family Mental Health & Community Psychiatry
  • Curtis, Lesley H., Professor in Population Health Sciences, Medicine, General Internal Medicine